Some registered account users are experiencing password recognition issues. The issue appears to have been triggered by a PHP update last night. If this is occurring, please try logging in and using the "forgot password?" utility. Bear in mind auto-generated password reset emails may appear in your spam folder. If this does not work, please click the "Contact Us" option near the lower right hand corner of the index page to contact me via email.
Thank you for your patience!
- M.W.
Thank you for your patience!
- M.W.
COVID-19 Science discussion
Re: COVID-19 Science discussion
There was a story on 60 Minutes last week about that.
The censorship king from out of state.
Re: COVID-19 Science discussion
Been quite a while since any updates to this thread.
Here one:
I ran across a similar study on HCQ but can't find the link right now.
Here one:
https://journals.lww.com/americantherap ... the.4.aspxConclusions:
Meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance. Furthermore, results from numerous controlled prophylaxis trials report significantly reduced risks of contracting COVID-19 with the regular use of ivermectin. Finally, the many examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an oral agent effective in all phases of COVID-19 has been identified.
I ran across a similar study on HCQ but can't find the link right now.
Re: COVID-19 Science discussion
So, we should be taking heartworm medicine?????
You're never too old to learn something stupid.
- MotorCityRadioFreak
- Posts: 7333
- Joined: Wed Jul 29, 2020 6:26 am
- Location: Warren, MI
Re: COVID-19 Science discussion
Too a bad it's just not true.km1125 wrote: ↑Wed Jun 23, 2021 4:54 pm Been quite a while since any updates to this thread.
Here one:https://journals.lww.com/americantherap ... the.4.aspxConclusions:
Meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance. Furthermore, results from numerous controlled prophylaxis trials report significantly reduced risks of contracting COVID-19 with the regular use of ivermectin. Finally, the many examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an oral agent effective in all phases of COVID-19 has been identified.
I ran across a similar study on HCQ but can't find the link right now.
They/them, non-binary and proud.
Remember that “2000 Mules” was concocted by a circus of elephants.
The right needs to stop worry about what’s between people’s legs. Instead, they should focus on what’s between their ears.
Audacity sucks.
Remember that “2000 Mules” was concocted by a circus of elephants.
The right needs to stop worry about what’s between people’s legs. Instead, they should focus on what’s between their ears.
Audacity sucks.
Re: COVID-19 Science discussion
Been quite a while since this thread has been updated, but thought this study was worthy of a post:
I think one of the more interesting aspects of the study was this "The group will also continue studying the 18 people who didn't get sick despite receiving the same amount of virus. ". There must be something to that "natural immunity" thing!! That's HALF of the study's population.
https://medicalxpress.com/news/2022-04- ... ovid-.html
First human challenge trial shows how COVID-19 strikes
A group of 36 volunteers have completed the first human challenge study of COVID-19, after being given the virus and then monitored to examine what happened to them after infection.
Researchers from the Imperial College of London learned a great deal about the virus during the initial study period in March 2021 and in follow-up assessments, including the fact that a tiny 10-micron droplet from a cough or sneeze can make someone sick, according to the findings, which were published Thursday in the journal Nature Medicine.
Other findings include that it only takes two days after a person is infected to start shedding virus, and that people shed a lot of virus before they show symptoms.
Challenge studies are controversial because they carry some risk, even with safeguards, but they are valuable for being able to follow the course of a virus from start to finish. The success of this study may pave the way for future challenge studies in low-risk individuals, CNN reported.
"Really, there's no other type of study where you can do that, because normally, patients only come to your attention if they have developed symptoms, and so you miss all of those preceding days when the infection is brewing," lead study author Dr. Christopher Chiu, an infectious disease physician and immunologist at Imperial College London, told CNN.
For this study, the 36 volunteers were between the ages 18 and 30 and had no risk factors for severe COVID-19.
The research team infected the group with a tiny drop of fluid of the original virus strain that was delivered through a thin tube inserted in their noses.
The patients were infected in phases as a precaution, with the first 10 individuals given the antiviral drug remdesivir to reduce their chances of severe disease, which was deemed unnecessary. They could also have been given monoclonal antibodies, but no one received them.
Researchers monitored the patients 24 hours a day while they stayed for two weeks in rooms at London's Royal Free Hospital.
Of the 36 patients, 18 became infected. Two of those never developed symptoms. Those who were ill had mild cases with stuffy noses, congestion, sneezing and sore throats. None of the patients developed lung problems, possibly because of their good health or the fact that they were given small amounts of virus.
About 83% did lose their sense of smell, at least partially. Six months after the study ended, one person has not had their sense of smell return, but it is improving.
Researchers also gave the participants thinking tests, to check their short-term memory and reaction time, which they are still assessing.
The study volunteers shed virus for about 6.5 days, on average, or up to 12 days, even if they had no symptoms.
The virus showed up on nose swabs after 58 hours and at the back of the throat after 40 hours. Rapid, at-home tests did well at diagnosing infection when a person was contagious, before 70% or 80% of viable virus was generated.
Chiu's team plans another challenge study, this time with vaccinated people infected with the Delta variant.
The group will also continue studying the 18 people who didn't get sick despite receiving the same amount of virus. Those individuals also never developed any antibodies and were screened for closely related viruses to rule out cross-protection.
"There are lots of other things that help protect us," Chiu said. "There are barriers in the nose. There are different kinds of proteins and things which are very ancient, primordial, protective systems, and they are likely to have been contributing to them not being infected, and we're really interested in trying to understand what those are."
Dr. Kathryn Edwards, a pediatric infectious disease specialist at Vanderbilt University who wrote an editorial published with the study, said the research offers important information about infection with the new coronavirus.
Blood and tissue samples collected for the study will be analyzed for years to come, she said.
"I think those are all in the freezer, so to speak, and are being dissected. So, I think that should be very powerful," Edwards told CNN.
I think one of the more interesting aspects of the study was this "The group will also continue studying the 18 people who didn't get sick despite receiving the same amount of virus. ". There must be something to that "natural immunity" thing!! That's HALF of the study's population.
https://medicalxpress.com/news/2022-04- ... ovid-.html
First human challenge trial shows how COVID-19 strikes
A group of 36 volunteers have completed the first human challenge study of COVID-19, after being given the virus and then monitored to examine what happened to them after infection.
Researchers from the Imperial College of London learned a great deal about the virus during the initial study period in March 2021 and in follow-up assessments, including the fact that a tiny 10-micron droplet from a cough or sneeze can make someone sick, according to the findings, which were published Thursday in the journal Nature Medicine.
Other findings include that it only takes two days after a person is infected to start shedding virus, and that people shed a lot of virus before they show symptoms.
Challenge studies are controversial because they carry some risk, even with safeguards, but they are valuable for being able to follow the course of a virus from start to finish. The success of this study may pave the way for future challenge studies in low-risk individuals, CNN reported.
"Really, there's no other type of study where you can do that, because normally, patients only come to your attention if they have developed symptoms, and so you miss all of those preceding days when the infection is brewing," lead study author Dr. Christopher Chiu, an infectious disease physician and immunologist at Imperial College London, told CNN.
For this study, the 36 volunteers were between the ages 18 and 30 and had no risk factors for severe COVID-19.
The research team infected the group with a tiny drop of fluid of the original virus strain that was delivered through a thin tube inserted in their noses.
The patients were infected in phases as a precaution, with the first 10 individuals given the antiviral drug remdesivir to reduce their chances of severe disease, which was deemed unnecessary. They could also have been given monoclonal antibodies, but no one received them.
Researchers monitored the patients 24 hours a day while they stayed for two weeks in rooms at London's Royal Free Hospital.
Of the 36 patients, 18 became infected. Two of those never developed symptoms. Those who were ill had mild cases with stuffy noses, congestion, sneezing and sore throats. None of the patients developed lung problems, possibly because of their good health or the fact that they were given small amounts of virus.
About 83% did lose their sense of smell, at least partially. Six months after the study ended, one person has not had their sense of smell return, but it is improving.
Researchers also gave the participants thinking tests, to check their short-term memory and reaction time, which they are still assessing.
The study volunteers shed virus for about 6.5 days, on average, or up to 12 days, even if they had no symptoms.
The virus showed up on nose swabs after 58 hours and at the back of the throat after 40 hours. Rapid, at-home tests did well at diagnosing infection when a person was contagious, before 70% or 80% of viable virus was generated.
Chiu's team plans another challenge study, this time with vaccinated people infected with the Delta variant.
The group will also continue studying the 18 people who didn't get sick despite receiving the same amount of virus. Those individuals also never developed any antibodies and were screened for closely related viruses to rule out cross-protection.
"There are lots of other things that help protect us," Chiu said. "There are barriers in the nose. There are different kinds of proteins and things which are very ancient, primordial, protective systems, and they are likely to have been contributing to them not being infected, and we're really interested in trying to understand what those are."
Dr. Kathryn Edwards, a pediatric infectious disease specialist at Vanderbilt University who wrote an editorial published with the study, said the research offers important information about infection with the new coronavirus.
Blood and tissue samples collected for the study will be analyzed for years to come, she said.
"I think those are all in the freezer, so to speak, and are being dissected. So, I think that should be very powerful," Edwards told CNN.
- MotorCityRadioFreak
- Posts: 7333
- Joined: Wed Jul 29, 2020 6:26 am
- Location: Warren, MI
Re: COVID-19 Science discussion
Natural immunity is short lived and is no guarantee that one will not be reinfected. If natural immunity were truly a thing, the pandemic would have ended by the end of 2020. As Matt would say, death is the only guaranteed natural immunity.
They/them, non-binary and proud.
Remember that “2000 Mules” was concocted by a circus of elephants.
The right needs to stop worry about what’s between people’s legs. Instead, they should focus on what’s between their ears.
Audacity sucks.
Remember that “2000 Mules” was concocted by a circus of elephants.
The right needs to stop worry about what’s between people’s legs. Instead, they should focus on what’s between their ears.
Audacity sucks.
Re: COVID-19 Science discussion
"Short lived"?? Where's the scientific proof of that??
In this study, you have HALF the folks who they attempted to PURPOSELY infect and who never got infected. THAT is "natural immunity" and something their own body acquired over their 18-30 year old lifespan. It would be interesting to wait a year or so and try to infect that same group of 36 folks and see if the same 18 resist infection just as well, and see who among the remaining "previously infected" get infected again.
Some folks probably have a propensity to be infected and can get reinfected over and over and others have the ability (natural ability) to resist infection and that capability would likely last their entire lives.
In this study, you have HALF the folks who they attempted to PURPOSELY infect and who never got infected. THAT is "natural immunity" and something their own body acquired over their 18-30 year old lifespan. It would be interesting to wait a year or so and try to infect that same group of 36 folks and see if the same 18 resist infection just as well, and see who among the remaining "previously infected" get infected again.
Some folks probably have a propensity to be infected and can get reinfected over and over and others have the ability (natural ability) to resist infection and that capability would likely last their entire lives.